Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xanamem in MDD with Cognitive Impairment
NCT05657691Phase 2Completed
- Sponsor
- Actinogen Medical Limited
- Start
- Nov 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) and cognitive impairment comparing 10 mg Xanamem with Placebo (2 arms). Primary endpoints: Efficacy of Xanamem on attention, including working memory at 6 weeks and Evaluation of the short-term safety and tolerability of Xanamem at 6 weeks. Started Nov 2022; status: completed.
02
Drugs
emestedastat
03
Conditions
major depressive disorder (MDD)cognitive impairment
Beyond the preview
Go deeper on NCT05657691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05657691.